Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

NewsVoir New Delhi [India] 3 Indraprastha Apollo Hospitals proudly announces the launch of its Heart Valve Clinic a dedicated ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Caranx hopes its AI software will make TAVI-TAVR procedures more accessible. Credit: surassawadee via Shutterstock. · Medical ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Indraprastha Apollo Hospitals has launched a Heart Valve Clinic, offering advanced care for heart valve disorders. The clinic boasts cutting-edge technology and a multidisciplinary team for ...

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

The American Heart Association has issued its heart disease and stroke statistical update for 2025, which provides an ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve Replacement (TAVR). This alternative access procedure provides a critical, less ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

At baseline, the mechanical valve group tended to be younger (55.7 vs 65.2) and had less aortic stenois (82.4% vs 89.5%), but ...